Literature DB >> 20175690

Validation of the American Thoracic Society-Infectious Diseases Society of America guidelines for hospital-acquired pneumonia in the intensive care unit.

Miquel Ferrer1, Adamantia Liapikou, Mauricio Valencia, Mariano Esperatti, Anna Theessen, Jose Antonio Martinez, Jose Mensa, Antoni Torres.   

Abstract

BACKGROUND: The 2005 guidelines of the American Thoracic Society-Infectious Diseases Society of America Guidelines for Hospital for managing hospital-acquired pneumonia classified patients according to time of onset and risk factors for potentially drug-resistant microorganisms to select the empirical antimicrobial treatment. We assessed the microbial prediction and validated the adequacy of these guidelines for antibiotic strategy.
METHODS: We prospectively observed 276 patients with intensive care unit-acquired pneumonia. We classified patients into group 1 (early onset without risk factors for potentially drug-resistant microorganisms; 38 patients) and group 2 (late onset or risk factors for potentially drug-resistant microorganisms; 238 patients). We determined the accuracy of guidelines to predict causative microorganisms and the influence of guidelines adherence in patients' outcome.
RESULTS: Microbial prediction was lower in group 1 than in group 2 (12 [50%] of 24 vs 119 [92%] of 129; P < .001) mainly because of potentially drug-resistant microorganisms in 10 patients (26%) from group 1. Guideline adherence was higher in group 2 (153 [64%] vs 7 [18%]; P < .001). Guideline adherence resulted in more treatment adequacy than did nonadherence (69 [83%] vs 45 [64%]; P = .013) and a trend toward better response to empirical treatment in group 2 only but did not influence mortality. Reclassifying patients according to the risk factors for potentially drug-resistant microorganisms of the former 1996 American Thoracic Society guidelines increased microbial prediction in group 1 to 21 (88%; P = .014); all except 1 patient with potentially drug-resistant microorganisms were correctly identified by these guidelines.
CONCLUSIONS: The 2005 guidelines predict potentially drug-resistant microorganisms worse than the 1996 guidelines. Adherence to guidelines resulted in more adequate treatment and a trend to a better clinical response in group 2, but it did not influence mortality.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20175690     DOI: 10.1086/651075

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  11 in total

Review 1.  Are we ready for novel detection methods to treat respiratory pathogens in hospital-acquired pneumonia?

Authors:  Andrea Endimiani; Kristine M Hujer; Andrea M Hujer; Sebastian Kurz; Michael R Jacobs; David S Perlin; Robert A Bonomo
Journal:  Clin Infect Dis       Date:  2011-05       Impact factor: 9.079

2.  Potentially resistant microorganisms in intubated patients with hospital-acquired pneumonia: the interaction of ecology, shock and risk factors.

Authors:  Ignacio Martin-Loeches; Maria Deja; Despoina Koulenti; George Dimopoulos; Brian Marsh; Antonio Torres; Michael S Niederman; Jordi Rello
Journal:  Intensive Care Med       Date:  2013-01-29       Impact factor: 17.440

3.  ATS Core Curriculum 2016. Part IV. Adult Pulmonary Medicine Core Curriculum.

Authors:  Gaëtane C Michaud; Colleen L Channick; Anica C Law; Jessica B McCannon; MaryEllen Antkowiak; Garth Garrison; David Sayah; Richard H Huynh; Anna K Brady; Rosemary Adamson; Hilary DuBrock; Praveen Akuthota; Chad Marion; Charles Dela Cruz; James A Town; Başak Çoruh; Carey C Thomson
Journal:  Ann Am Thorac Soc       Date:  2016-07

4.  A week seems to be weak: tailoring duration of antibiotic treatment in Gram-negative ventilator-associated pneumonia.

Authors:  Ignacio Martin-Loeches; Antoni Torres
Journal:  Crit Care       Date:  2013-01-21       Impact factor: 9.097

5.  Development and implementation of a performance improvement project in adult intensive care units: overview of the Improving Medicine Through Pathway Assessment of Critical Therapy in Hospital-Acquired Pneumonia (IMPACT-HAP) study.

Authors:  Julie E Mangino; Paula Peyrani; Kimbal D Ford; Daniel H Kett; Marcus J Zervos; Verna L Welch; Ernesto G Scerpella; Julio A Ramirez
Journal:  Crit Care       Date:  2011-01-25       Impact factor: 9.097

6.  Tumor necrosis factor receptor 1 (TNFRI) for ventilator-associated pneumonia diagnosis by cytokine multiplex analysis.

Authors:  Ignacio Martin-Loeches; Lieuwe D Bos; Pedro Povoa; Paula Ramirez; Marcus J Schultz; Antoni Torres; Antonio Artigas
Journal:  Intensive Care Med Exp       Date:  2015-09-16

7.  Introducing the Comprehensive Unit-based Safety Program for mechanically ventilated patients in Saudi Arabian Intensive Care Units.

Authors:  Raymond M Khan; Maha Aljuaid; Hanan Aqeel; Mohammed M Aboudeif; Shaimaa Elatwey; Rajeh Shehab; Yasser Mandourah; Khalid Maghrabi; Hassan Hawa; Imran Khalid; Ismael Qushmaq; Asad Latif; Bickey Chang; Sean M Berenholtz; Sultan Tayar; Khloud Al-Harbi; Amin Yousef; Anas A Amr; Yaseen M Arabi
Journal:  Ann Thorac Med       Date:  2017 Jan-Mar       Impact factor: 2.219

Review 8.  Update on ventilator-associated pneumonia.

Authors:  Jean-Francois Timsit; Wafa Esaied; Mathilde Neuville; Lila Bouadma; Bruno Mourvllier
Journal:  F1000Res       Date:  2017-11-29

Review 9.  Update of the treatment of nosocomial pneumonia in the ICU.

Authors:  Rafael Zaragoza; Pablo Vidal-Cortés; Gerardo Aguilar; Marcio Borges; Emili Diaz; Ricard Ferrer; Emilio Maseda; Mercedes Nieto; Francisco Xavier Nuvials; Paula Ramirez; Alejandro Rodriguez; Cruz Soriano; Javier Veganzones; Ignacio Martín-Loeches
Journal:  Crit Care       Date:  2020-06-29       Impact factor: 9.097

10.  Early-onset ventilator-associated pneumonia in adults randomized clinical trial: comparison of 8 versus 15 days of antibiotic treatment.

Authors:  Gilles Capellier; Hélène Mockly; Claire Charpentier; Djillali Annane; Gilles Blasco; Thibault Desmettre; Antoine Roch; Christophe Faisy; Joel Cousson; Samuel Limat; Mariette Mercier; Laurent Papazian
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.